UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) June 21, 2007
Neurologix, Inc.
(Exact Name of Registrant as Specified in Charter)
Commission File Number: 000-13347
|
Delaware |
|
06-1582875 |
|
(State or other Jurisdiction of Incorporation) |
|
(I.R.S. Employer Identification No.) |
One Bridge Plaza, Fort Lee, New Jersey 07024
(Address of Principal Executive Offices)
(Zip Code)
(201) 592-6451
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation F-D Disclosure
On June 21, 2007, Neurologix, Inc. issued a press release announcing the publication in the June 23 issue of the journal The Lancet of the Company's results from its Phase I trial for Parkinson’s disease. A copy of the release is attached hereto as Exhibit 99.1.
The information, including the exhibit attached hereto, in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
99.1 |
Press release dated June 21, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 21, 2007
|
|
NEUROLOGIX, INC. | ||
|
|
| ||
|
|
| ||
|
|
By: |
/s/ Marc L. Panoff |
|
|
|
|
/s/ Marc L. Panoff | |